Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

Joana Savva-Bordalo,João Ramalho-Carvalho,Manuela Pinheiro,Vera L. Costa,Ângelo Rodrigues,Paula C. Dias,Isabel Veiga,Manuela Machado,Manuel R. Teixeira,Rui Henrique,Carmen Jerónimo

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

2010

Joana Savva-Bordalo
João Ramalho-Carvalho
Manuela Pinheiro
Vera L. Costa
Ângelo Rodrigues
Paula C. Dias
Isabel Veiga
Manuela Machado
Manuel R. Teixeira
Rui Henrique
Carmen Jerónimo

Background Severe toxicity to 5-fluorouracil (5-FU) based chemotherapy in gastrointestinal cancer has been associated with constitutional genetic alterations of the dihydropyrimidine dehydrogenase gene (DPYD).

Keywords:

Cancer research
Bisulfite sequencing
Pathology
Genetic predisposition
DNA methylation
Fluorouracil
Medicine
DPYD
Mucositis
Gastrointestinal cancer
Chemotherapy
gene rearrangement
Surgical oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations